Cell and Gene Meeting on the Mesa
- Presentation Title: Transformative Gene Therapies for the Treatment of Rare Inherited Retinal Diseases
- Presentation Content: Three-month pediatric and 18-month adult clinical data from the Phase 1/2 trial of OPGx-LCA5 in patients with Leber congenital amaurosis type 5 (LCA5)
- Date/Time: Monday, October 6, 2025, 9:15–9:30 am MT
- Presenter: George Magrath, M.D., Chief Executive Officer, Opus Genetics
- Location: Arizona Biltmore, Phoenix, AZ